INFLIXIMAB

作品数：230被引量：491H指数：10
导出分析报告
相关领域：医药卫生更多>>
相关作者：黄烽张江林张莉芸张奉春朱剑更多>>
相关机构：中国人民解放军总医院北京协和医院广州市第一人民医院南京医科大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金广东省中医药管理局基金中西医结合科研计划课题深圳市医学重点学科建设基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Evaluation of biological therapies in autoimmune hepatitis:A casebased systematic review
《World Journal of Gastrointestinal Pathophysiology》2025年第1期1-13,共13页Haifa Eldew Jonathan Soldera 
BACKGROUND Autoimmune hepatitis(AIH)is typically treated with immunomodulators and steroids.However,some patients are refractory to these treatments,necessitating alternative approaches.Biological therapies have recen...
关键词：Autoimmune hepatitis Biological therapies BELIMUMAB RITUXIMAB BASILIXIMAB INFLIXIMAB ADALIMUMAB 
Atypical Presentation of Crohn’s Disease: Diagnostic Challenges in a Clinical Case
《Case Reports in Clinical Medicine》2025年第1期10-14,共5页Catarina Pinto Silva Rita Sevivas Flávia Ramos Dany Cruz Cristina Marques Beatriz Rosa Márcia Ribeiro Carlos S. Oliveira 
Introduction: Crohn’s Disease (CD) is a chronic inflammatory disorder with a heterogeneous presentation. While diarrhea, abdominal pain, and weight loss are hallmarks, atypical manifestations can obscure the diagnosi...
关键词：Crohn’s Disease Atypical Presentation Diagnostic Challenges Inflammatory Markers INFLIXIMAB IMAGING 
Anthocyanins from purple corn affect gut microbiota and metabolome in inflammatory bowel disease patients under infliximab infusion: the SiCURA pilot study
《Food Science and Human Wellness》2024年第6期3536-3543,共8页Mirco Vacca Eduardo Maria Sommella Marina Liso Giulio Verna Aurelia Scarano Annamaria Sila Margherita Curlo Mauro Mastronardi Katia Petroni Chiara Tonelli Bruno Di Jeso Angelo Santino Vincenzo Vestuto Fabrizio Merciai Gianluigi Giannelli Pietro Campiglia Maria De Angelis Marcello Chieppa Francesco Maria Calabrese 
supported by the grant from Italian Ministry of Health Ricerca Corrente 2023 IRCCS“S.de Bellis”;by the Apulia Region grant SiCURA“Soluzioni Innovative per la gestione del paziente e il follow up terapeutico della Colite UlceRosA”(KC3U5Y1).
Nowadays,inflammatory bowel disease(IBD)-patient therapies are mainly based on corticosteroid,thiopurine,and immunomodulator treatments.Patients with active disease,that do not respond to corticosteroid and/or thiopur...
关键词：Inflammatory bowel disease infliximab infusion ANTIOXIDANTS NUTRIGENOMICS Adjuvant therapy 
Navigating treatment resistance:Janus kinase inhibitors for ulcerative colitis
《World Journal of Clinical Cases》2024年第24期5468-5472,共5页Jonathan Soldera 
The management of refractory ulcerative colitis(UC)and acute severe UC(ASUC)is challenging due to the lack of standardized approaches in cases resistant to multiple treatments.In this editorial,I investigate the effic...
关键词：Inflammatory bowel disease Ulcerative colitis Janus kinase inhibitor Upadacitinib Tofacitinib INFLIXIMAB 
Nursing Care of Infliximab for Injection in Crohn’s Disease
《Yangtze Medicine》2024年第2期41-47,共7页Liu Yang Xiaomei Cai Zhimin Tian 
Objective: To summarize the nursing experience of infliximab injection in the treatment of Crohns disease. Methods: 25 patients with Crohns disease admitted to our hospital from November 2017 to February 2024 were tre...
关键词：Crohn’s Disease INFLIXIMAB Adverse Reactions NURSING 
Long-term outcome of stem cell transplantation with and without anti-tumor necrotic factor therapy in perianal fistula with Crohn’s disease
《World Journal of Stem Cells》2024年第3期257-266,共10页Min Young Park Yong Sik Yoon Jae Ha Park Jong Lyul Lee Chang Sik Yu 
Supported by the grants from the Asan Institute for Life Sciences,Asan Medical Center,Seoul,Korea,No.2019IF0593 and No.2020IP0039.
BACKGROUND Stem cell transplantation is a promising therapeutic option for curing perianal fistula in Crohn’s disease(CD).Anti-tumor necrotic factor(TNF)therapy combined with drainage procedure is effective as well.H...
关键词：Crohn’s disease ANUS FISTULA Stem cell transplantation Tumor necrosis factor-alpha inhibitors INFLIXIMAB 
Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab:A case report被引量：3
《World Journal of Clinical Cases》2024年第9期1685-1690,共6页Xuan Xu Jing-Wen Jiang Bing-Yun Lu Xia-Xi Li 
Supported by Shenzhen Science and Technology Program,No.JCYJ20220530154013031;Guangdong Province Health and Health Appropriate Technology Promotion Project,No.2023385;Guangdong Province Grassroots Science Popularization Action Plan,No.20240205.
BACKGROUND Many patients with ulcerative colitis(UC)do not respond well to,or tolerate conventional and biological therapies.There is currently no consensus on the treatment of refractory UC.Studies have demonstrated ...
关键词：Upadacitinib Refractory ulcerative colitis Primary nonresponse INFLIXIMAB Vedolizumab Case report 
Comparison of accelerated and standard infliximab induction regimens in acute severe ulcerative colitis using propensity score analysis:a retrospective multicenter study in China
《Gastroenterology Report》2024年第1期279-288,共10页Xinyu Liu Hui Li Feng Tian Ying Xie Xiaoqi Zhang Min Zhi Min Zhang Xiaomei Song Hong Guo Xiaofei Li Jie Liang Jun Shen Yue Li 
supported by National High Level Hospital Clinical Research Funding[grant number 2022-PUMCH-B-022];CAMS Innovation Fund for Medical Sciences(CIFMS)from Chinese Academy of Medical Sciences[grant number 2021-I2M-1-062].
Background:The optimal regimen of infliximab salvage in acute severe ulcerative colitis(ASUC)patients remains controversial.This study aimed to compare accelerated and standard infliximab induction in Chinese ASUC pat...
关键词：acute severe ulcerative colitis INFLIXIMAB accelerated induction propensity score analysis 
HLA-DQA1^(*)05 correlates with increased risk of anti-drug antibody development and reduced response to infliximab in Chinese patients with Crohn’s disease
《Gastroenterology Report》2024年第1期348-354,共7页Wei Wang Qi Zhang Junzhang Zhao Tao Liu Jiayin Yao Xiang Peng Min Zhi Min Zhang 
funded by the China Crohn’s&Colitis Foundation[grant number CCCF-QF-2022A53-2].
Background:The efficacy of anti-TNF therapy in Crohn’s disease(CD),such as infliximab,is often compromised by the development of anti-drug antibodies(ADAs).The genetic variation HLA-DQA1*05 has been linked to the imm...
关键词：Crohn’s disease INFLIXIMAB HLA-DQA1*05 anti-drug antibodies 
Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis
《World Journal of Gastrointestinal Surgery》2024年第2期571-584,共14页Fang-Yuan Zheng Kai-Si Yang Wen-Cheng Min Xin-Zhu Li Yu Xing Shuai Wang Ying-Shi Zhang Qing-Chun Zhao 
Supported by National College Students Innovation and Entrepreneurship Training Program of Shenyang Pharmaceutical University,No.202210163003.
BACKGROUND The efficacy and safety of anti-tumor necrosis factor-α(TNF-α)monoclonal antibody therapy[adalimumab(ADA)and infliximab(IFX)]with therapeutic drug monitoring(TDM),which has been proposed for inflammatory ...
关键词：Inflammatory bowel disease Therapeutic drug monitoring ADALIMUMAB INFLIXIMAB Network meta-analysis 
全选清除导出
共23页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部